In this context, inhibition of the binding affinity of the Spike protein to the ACE2 has been the focus for therapeutic targets, and rapid-COVID-19-on-a-chip has provided high-throughput analyses using the patient-specific whole blood and pseudo-SARS-CoV-2 virus. The gene discussed is ACE2; the disease is COVID-19.